Atea Pharmaceuticals Inc
NASDAQ:AVIR
Atea Pharmaceuticals Inc
NASDAQ:AVIR
Price:
6.1
USD
0.83%
Market Closed
Market Cap:
$476.6m
Income Statement
Earnings Waterfall
Atea Pharmaceuticals Inc
Atea Pharmaceuticals Inc
Income Statement
Atea Pharmaceuticals Inc
Atea Pharmaceuticals Inc
Currency: USD
| Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
49
N/A
|
115
+136%
|
175
+53%
|
208
+19%
|
351
+69%
|
285
-19%
|
225
-21%
|
192
-15%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | ||||||||||||||||||||||||||
| Operating Expenses |
(15)
|
(16)
|
(17)
|
(23)
|
(37)
|
(50)
|
(68)
|
(85)
|
(120)
|
(131)
|
(137)
|
(137)
|
(111)
|
(115)
|
(116)
|
(120)
|
(120)
|
(119)
|
(126)
|
(126)
|
(132)
|
(140)
|
(145)
|
(160)
|
(179)
|
|
| Selling, General & Administrative |
(4)
|
(5)
|
(6)
|
(9)
|
(22)
|
(29)
|
(39)
|
(47)
|
(46)
|
(50)
|
(50)
|
(50)
|
(49)
|
(49)
|
(50)
|
(51)
|
(50)
|
(49)
|
(48)
|
(47)
|
(49)
|
(46)
|
(43)
|
(39)
|
(33)
|
|
| Research & Development |
(10)
|
(11)
|
(11)
|
(14)
|
(15)
|
(21)
|
(29)
|
(39)
|
(74)
|
(82)
|
(87)
|
(87)
|
(62)
|
(66)
|
(66)
|
(69)
|
(70)
|
(69)
|
(76)
|
(78)
|
0
|
(93)
|
(103)
|
(121)
|
(147)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(83)
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(15)
N/A
|
(16)
-10%
|
(17)
-6%
|
(23)
-33%
|
12
N/A
|
65
+440%
|
107
+65%
|
123
+15%
|
232
+89%
|
154
-34%
|
88
-43%
|
55
-37%
|
(111)
N/A
|
(115)
-3%
|
(116)
-1%
|
(120)
-4%
|
(120)
0%
|
(119)
+1%
|
(126)
-6%
|
(126)
0%
|
(132)
-4%
|
(140)
-6%
|
(145)
-4%
|
(160)
-10%
|
(179)
-12%
|
|
| Pre-Tax Income | ||||||||||||||||||||||||||
| Interest Income Expense |
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
6
|
11
|
17
|
24
|
27
|
29
|
30
|
29
|
28
|
0
|
24
|
21
|
19
|
16
|
|
| Non-Reccuring Items |
0
|
(0)
|
(6)
|
(14)
|
(23)
|
(41)
|
(65)
|
(85)
|
(94)
|
(89)
|
(63)
|
(25)
|
(20)
|
(15)
|
(17)
|
(38)
|
(44)
|
(73)
|
(78)
|
(74)
|
(61)
|
(22)
|
(11)
|
(5)
|
(1)
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
26
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(14)
N/A
|
(16)
-14%
|
(22)
-40%
|
(36)
-63%
|
(11)
+70%
|
24
N/A
|
43
+79%
|
38
-11%
|
139
+265%
|
66
-53%
|
26
-61%
|
36
+40%
|
(120)
N/A
|
(113)
+6%
|
(109)
+3%
|
(130)
-19%
|
(135)
-4%
|
(163)
-20%
|
(175)
-7%
|
(173)
+1%
|
(167)
+3%
|
(138)
+17%
|
(135)
+2%
|
(146)
-8%
|
(165)
-13%
|
|
| Net Income | ||||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
(7)
|
(13)
|
(17)
|
(17)
|
(10)
|
(0)
|
4
|
3
|
3
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
6
|
|
| Income from Continuing Operations |
(14)
|
(16)
|
(22)
|
(36)
|
(11)
|
24
|
35
|
25
|
121
|
48
|
16
|
36
|
(116)
|
(109)
|
(106)
|
(131)
|
(136)
|
(163)
|
(176)
|
(174)
|
(168)
|
(140)
|
(136)
|
(147)
|
(158)
|
|
| Net Income (Common) |
(14)
N/A
|
(16)
-14%
|
(22)
-40%
|
(36)
-63%
|
(11)
+70%
|
24
N/A
|
35
+48%
|
25
-30%
|
121
+391%
|
48
-60%
|
16
-68%
|
36
+130%
|
(116)
N/A
|
(109)
+6%
|
(106)
+3%
|
(131)
-24%
|
(136)
-4%
|
(163)
-20%
|
(176)
-8%
|
(174)
+1%
|
(168)
+4%
|
(140)
+17%
|
(136)
+3%
|
(147)
-8%
|
(158)
-8%
|
|
| EPS (Diluted) |
-0.17
N/A
|
-0.19
-12%
|
-0.27
-42%
|
-0.45
-67%
|
-0.13
+71%
|
0.25
N/A
|
0.39
+56%
|
0.29
-26%
|
1.37
+372%
|
0.58
-58%
|
0.18
-69%
|
0.42
+133%
|
-1.39
N/A
|
-1.32
+5%
|
-1.28
+3%
|
-1.58
-23%
|
-1.63
-3%
|
-1.96
-20%
|
-2.1
-7%
|
-2.07
+1%
|
-2
+3%
|
-1.65
+18%
|
-1.61
+2%
|
-1.85
-15%
|
-2.02
-9%
|
|
Switch to:
Switch to:
See Also
Discover More
